2005
DOI: 10.1016/j.clim.2005.04.010
|View full text |Cite
|
Sign up to set email alerts
|

Regulation of p38 MAP kinase in CD4 lymphocytes by infliximab therapy in patients with rheumatoid arthritis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
10
0

Year Published

2006
2006
2014
2014

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 15 publications
(11 citation statements)
references
References 28 publications
1
10
0
Order By: Relevance
“…This TNF-α blocker has been shown to have an estimated half-life of 8 to 9.5 days in serum after a 3 mg/kg dose and its serum concentration decline more slowly when the drug is given in combination with disease-modifying anti-rheumatic drugs such as MTX [24]. Garfield and coworkers have previously demonstrated that infliximab has no effect on the number of PBMC [25]. After infliximab treatment, the activated p38 MAP kinase (MAPK) level in CD4+ T cells was markedly reduced while the level of total p38 MAPK and the number of TNF-α producing cells were unchanged [25,26].…”
Section: Discussionmentioning
confidence: 96%
See 1 more Smart Citation
“…This TNF-α blocker has been shown to have an estimated half-life of 8 to 9.5 days in serum after a 3 mg/kg dose and its serum concentration decline more slowly when the drug is given in combination with disease-modifying anti-rheumatic drugs such as MTX [24]. Garfield and coworkers have previously demonstrated that infliximab has no effect on the number of PBMC [25]. After infliximab treatment, the activated p38 MAP kinase (MAPK) level in CD4+ T cells was markedly reduced while the level of total p38 MAPK and the number of TNF-α producing cells were unchanged [25,26].…”
Section: Discussionmentioning
confidence: 96%
“…Garfield and coworkers have previously demonstrated that infliximab has no effect on the number of PBMC [25]. After infliximab treatment, the activated p38 MAP kinase (MAPK) level in CD4+ T cells was markedly reduced while the level of total p38 MAPK and the number of TNF-α producing cells were unchanged [25,26]. Therefore, our study showed that infliximab exhibited an inhibitory effect on the circulating peripheral blood cells to release TNF-α upon stimulation, probably through the suppression of the activity of p38 MAPK in PBMC.…”
Section: Discussionmentioning
confidence: 97%
“…Recently, it has been postulated that Ras-mediated signaling pathways are involved in the activation of RA synovial fibroblasts and the destruction of bone in arthritic joints [127]. Specifically, Garfield et al [131] demonstrated that the CD4 + cells from RA patients treated with infliximab showed a decline of active p38 MAPK. This pathway is associated with IFN-γ production [90].…”
Section: Statins and Arthritis Rheumatoid As Prototypic Of Rheumatic mentioning
confidence: 98%
“…This inhibition of p38 MAPK can reduce inflammation in animal models and RA, suggesting that p38 MAPK cascade plays a role in the pathogenesis of inflammatory arthritis [156][157][158][159]. Garfield et al [131] demonstrated that anti-TNF-α treatment in RA patients decreased the levels of active p38 MAPK in CD4 + T-cells without effect of this pathway in other cells (macrophages and CD8 + T-cells). They proposed that TNF-α in RA patients increase p38 MAPK in CD4 + T-cells, thereby, promoting INF-γ and TNF-α production.…”
Section: Statins and Arthritis Rheumatoid As Prototypic Of Rheumatic mentioning
confidence: 99%
“…T cell functions associated with RA progression, including the Th1 immune response, are controlled by p38 (7,37). Although it has long been assumed that p38 activity is regulated mainly through the classic MAPK pathway, the Tyr 323 -dependent pathway is required for TCR-mediated p38 activation (26,30).…”
Section: Resultsmentioning
confidence: 99%